Creegan & Nassoura Financial Group’s Gilead Sciences GILD Stock Holding History

Creegan & Nassoura Financial Group’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-9,173	Closed	-$596K	–	69
2019 Q4	$596K	Buy	+9,173	New	+$597K	0.6%	54
2016 Q3	$960K	Buy	12,128 +1	+0%	+$81	1.12%	40
2016 Q2	$1.01M	Sell	12,127 -499	-4%	-$44.3K	1.2%	37
2016 Q1	$1.16M	Hold	12,626	–	–	1.37%	31
2015 Q4	$1.28M	Sell	12,626 -259	-2%	-$26.9K	1.45%	30
2015 Q3	$1.26M	Buy	12,885 +1	+0%	+$111	1.44%	28
2015 Q2	$1.51M	Hold	12,884	–	–	1.57%	30
2015 Q1	$1.26M	Sell	12,884 -250	-2%	-$25.4K	1.3%	35
2014 Q4	$1.24M	Buy	+13,134	New	+$1.36M	1.26%	35

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Creegan & Nassoura Financial Group's GILD Position: Q1 2020 in Review

Creegan & Nassoura Financial Group sold out of Gilead Sciences (GILD) in Q1 2020, closing a stake of 9,173 shares — an estimated $596K sold.

Creegan & Nassoura Financial Group first reported a position in GILD in Q4 2014 and held it in 9 quarters. The position peaked at $1.51M in Q2 2015. 1,643 funds tracked by Wall St. Rank hold GILD as of Q1 2020.

Creegan & Nassoura Financial Group reported no remaining Gilead Sciences position as of Q1 2020 after selling out during the quarter.
Creegan & Nassoura Financial Group sold 9,173 Gilead Sciences shares in Q1 2020, an estimated $596K.
Creegan & Nassoura Financial Group first reported a position in Gilead Sciences in Q4 2014 and held it in 9 quarters.
Creegan & Nassoura Financial Group's Gilead Sciences position peaked at $1.51M in Q2 2015.
1,643 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2020.

Based on Creegan & Nassoura Financial Group's 13F filing for Q1 2020, filed 15 May 2020.